Annual Report

Overview

The report describes FY 2022-23 performance for the company, including consolidated total revenue of Rs.30.69/- lakhs and a consolidated net loss of Rs. (70.71) Lakhs. It highlights the company's shift toward biopharma and continued pharmaceutical research, supported by its associate's 12 international granted patents. The workforce disclosure states that the company had only three employees.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2022-2023
Period: 1 April 2022 – 31 March 2023
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services